多西他赛疗程对CLEOPATRA研究临床结局的影响:探索性分析
该事后探索性分析基于CLEOPATRA III期随机对照试验,评估HER2阳性转移性乳腺癌患者接受多西他赛(D)联合曲妥珠单抗及帕妥珠单抗或安慰剂时,D疗程对临床结局的影响。调整帕妥珠单抗获益后,超过6周期D相比6周期并未显著改善无进展生存(PFS)或总生存(OS);无论D疗程长短,帕妥珠单抗均带来一致的PFS和OS获益。
要点
- 超过6周期多西他赛相比6周期未显著改善PFS(HR=0.80,P=0.0640)或OS(HR=0.88,P=0.3073)。
- 帕妥珠单抗相比安慰剂在各D疗程组均一致改善PFS和OS。
- 调整帕妥珠单抗获益后,D疗程延长未见额外显著临床获益。
核心结论
- 调整帕妥珠单抗获益后,超过6周期多西他赛相比6周期未显著改善PFS或OS。
- 无论多西他赛疗程长短,帕妥珠单抗联合曲妥珠单抗相比曲妥珠单抗联合安慰剂均改善临床结局。
研究设计与样本
- CLEOPATRA研究的事后探索性分析,III期随机对照试验。
- 纳入804例HER2阳性转移性乳腺癌患者,按多西他赛周期数分为<6D(n=119)、6D(n=210)和>6D(n=475)三组。
- 采用Kaplan-Meier法估计各治疗组内各D周期组的PFS和OS,并应用时间依赖多因素Cox回归估计调整风险比(HR)及95%置信区间(CI)。
主要发现
- 调整帕妥珠单抗 vs 安慰剂获益(PFS HR=0.61,95% CI 0.51-0.74,P<0.0001;OS HR=0.60,95% CI 0.49-0.74,P<0.0001)后,>6D vs 6D的PFS无显著改善(HR=0.80,95% CI 0.63-1.01,P=0.0640),OS亦无显著改善(HR=0.88,95% CI 0.69-1.12,P=0.3073)。
- 帕妥珠单抗 vs 安慰剂在各D疗程组均观察到PFS和OS的一致改善;PFS的HR在<6D、6D和>6D组分别为0.395、0.615和0.633(所有D周期组P<0.05);OS的HR分别为0.577、0.700和0.612(<6D和>6D组P<0.05)。
临床怎么用
- 对于HER2阳性转移性乳腺癌患者,含帕妥珠单抗和曲妥珠单抗的一线方案中,多西他赛超过6周期未显示显著额外获益,可考虑6周期作为参考。
- 帕妥珠单抗的获益不依赖于多西他赛疗程长短。
局限性
- 本研究为事后探索性分析,非预先设定的主要分析。
- 多西他赛周期分组非随机,可能存在混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination pertuzumab, trastuzumab, and docetaxel (D) is considered standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This post hoc, exploratory analysis of CLEOPATRA study data evaluated the clinical effects of D treatment duration within this regimen. The clinical benefits of pertuzumab and trastuzumab by different durations of D treatment were also evaluated. PATIENTS AND METHODS: Patients with HER2-positive metastatic breast cancer received trastuzumab and D plus pertuzumab or placebo. Clinical outcomes were analyzed by the number of D cycles that patients received (<6D, 6D, or >6D). Progression-free survival (PFS) and overall survival (OS) for each treatment arm within each D cycle group were estimated using the Kaplan-Meier approach. Time-dependent, multivariate Cox regression was applied to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for HER2-targeted therapy and D cycle groups. RESULTS: Overall, 804 patients received <6D (n = 119), 6D (n = 210), or >6D (n = 475) cycles. After adjusting for pertuzumab benefits versus placebo (PFS HR = 0.61, 95% CI 0.51-0.74, P < 0.0001; OS HR = 0.60, 95% CI, 0.49-0.74, P < 0.0001), >6D versus 6D cycles was not associated with statistically significant improvements in PFS (HR = 0.80, 95% CI 0.63-1.01, P = 0.0640) or OS (HR = 0.88, 95% CI 0.69-1.12, P = 0.3073). Consistent improvements in PFS and OS were observed with pertuzumab versus placebo, irrespective of D duration. The HRs for PFS were 0.395, 0.615, and 0.633 for <6D, 6D, and >6D cycles, respectively (P < 0.05 for all D cycle groups). Corresponding HRs for OS were 0.577, 0.700, and 0.612, respectively (P < 0.05 for <6D and >6D). CONCLUSIONS: After accounting for pertuzumab benefits, more than six cycles of D treatment was not associated with significant improvements in either PFS or OS compared with six cycles. The addition of pertuzumab to trastuzumab improved clinical outcomes versus trastuzumab plus placebo, regardless of D treatment duration. CLINICALTRIALS.GOV IDENTIFIER: NCT00567190.
引用
- Miles D, Im YH, Fung A, et al. Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial. Ann Oncol. 2017. PMID: 29112701. doi:10.1093/annonc/mdx406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。